Physician profile
Antonio Izzo
NPI 1720405863
$3,377.07
in general payments reported to CMS, 2019-2025
30 companies · $1,518 in 2025
The $1,518 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $225 · 2022: $433 · 2023: $407 · 2024: $794 · 2025: $1,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,719.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $837.70 | 2021-2025 | |
| Novo Nordisk INC | $518.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $386.43 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $335.22 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $183.19 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $156.97 | 2024-2025 | |
| Exact Sciences Corporation | $153.89 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.44 | 2021-2025 | Jardiance |
| Axsome Therapeutics, INC. | $74.33 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $68.45 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $51.67 | 2024-2025 | |
| Tolmar, INC. | $50.78 | 2024-2025 | Jatenzo |
| Abbott Laboratories | $41.25 | 2024-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $40.67 | 2023-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $38.07 | 2022-2025 | Spravato |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $35.85 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.57 | 2022 | |
| Alnylam Pharmaceuticals INC. | $27.55 | 2025 | Givlaari |
| Lundbeck LLC | $24.61 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $24.37 | 2025 | Ponvory |
| Xeris Pharmaceuticals, INC. | $21.16 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.80 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $17.84 | 2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $17.72 | 2023 | Trintellix |
| Renalytix Ai, INC. | $15.28 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.69 | 2022 | |
| Currax Pharmaceuticals LLC | $14.18 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.88 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.98 | 2021 | |
| Merck Sharp & Dohme LLC | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Izzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.